14 results about "Mitochondrial biogenesis" patented technology

The invention provides a potential therapeutic target for cardiac hypertrophy and heart failure, finds that the cardiac hypertrophy caused by pressure load can be obviously relieved by using adeno-associated virus (AVV9) as a carrier myocardial cell specific overexpression Ces1d gene, and finds that the Ces1d relieves the cardiac hypertrophy by promoting fatty acid oxidation; and a potential target and a new strategy are provided for heart failure treatment. According to the invention, Ces1d is taken as a regulation target, and the expression level of Ces1d is regulated, so that the fatty acid oxidation of myocardial cells can be obviously promoted, and the expression of fatty acid oxidation related genes such as Cpt1a, Cpt1b, Cpt2, Acadm, Acadvl and Acox1 can be up-regulated, thereby optimizing the utilization mode of a myocardial energy metabolism substrate; meanwhile, mitochondrial dysfunction and mitochondrial generation damage induced by pressure load can be improved. Therefore, the regulation strategy taking the Ces1d as the action target and the AVV9 as the carrier provides a new gene therapy technical approach for prevention and treatment of cardiac hypertrophy and related cardiovascular diseases, and has a good application prospect and a remarkable clinical potential value.

The invention belongs to the technical field of pharmacy, and particularly relates to application of spermidine in sepsis treatment. Experiments prove that spermidine can regulate mitochondrial biogenesis and inhibit mitochondrial excessive autophagy to remarkably improve mitochondrial quality, maintain mitochondrial homeostasis and relieve myocardial dysfunction and heart structure damage. In addition, spermidine can inhibit oxidative stress caused by excessive inflammatory response so as to recover normal functions of mitochondria. The spermidine has a potential treatment effect on sepsis and has a good clinical application prospect in treating sepsis and related diseases caused by excessive autophagy.

The present disclosure relates to highly purified (R)-3'-hydroxybutyl (R)-3'-hydroxybutyrate and biomedical uses thereof. In particular highly purified (R)-3'-hydroxybutyl (R)-3'-hydroxybutyrate, is provided for enhancing bodily function and treating various disease states. The methods described herein provide for production of a highly purified (R)-3'-hydroxybutyl (R)-3'-hydroxybutyrate via processes external to the human body and administering effective amounts of highly purified (R)-3'-hydroxybutyl (R)-3'-hydroxybutyrate to human subjects to achieve a range of therapeutic benefits, including but not limited to, one or more of: inhibiting inflammasome activation, reducing pro-inflammatory cytokines, improving insulin sensitivity, enhancing mitochondrial biogenesis, and promoting muscle protein synthesis. Additionally, highly purified (R)-3'-hydroxybutyl (R)-3'-hydroxybutyrate is administered in an amount and frequency conducive to one or more of: improving cognitive function, reducing oxidative stress, enhancing cardiovascular health, and supporting neuroprotection. Methods for manufacturing and purifying (R)-3'-hydroxybutyl (R)-3'-hydroxybutyrate compositions to ensure high specificity and efficacy in therapeutic applications are also provided.

This disclosure describes the characteristics of the “energetic” cancer stem cell (e-CSC) phenotype. This distinct sub-population of cancer stem cells (CSCs) has a unique energetic profile compared to bulk CSCs, being more glycolitic, having higher mitochondrial mass and elevated oxidative metabolism. e-CSCs also show an increased capacity to undergo cell cycle progression, enhanced anchorage-independent growth, and ALDH-positivity. The e-CSC phenotype presents new targets for cancer therapeutics, and in particular the anti-oxidant response, mitochondrial energy production, and mitochondrial biogenesis of e-CSCs makes them highly susceptible to mitochondrial inhibitors that target e-CSC anti-oxidant response, mitochondrial energy production, and mitochondrial biogenesis. Gene products for e-CSCs are disclosed, as well as classes of mitochondrial inhibiting therapeutic agents. Also disclosed are methods for identifying and separating e-CSCs front bulk cell populations.

The present invention discloses an anti-aging composition synergistically enhancing mitochondrial function with AKG and PQQ, belonging to the technical field of anti-aging. The composition comprises AKG, PQQ disodium salt, Agaricus bisporus extract, and a single excipient. AKG, in anhydrous crystal form as 2-oxoglutaric acid, directly participates in mitochondrial energy metabolism and provides core substrate support. PQQ disodium salt promotes mitochondrial biogenesis, ensuring structural renewal and maintaining mitochondrial activity. The β-glucan and ergothioneine naturally contained in the Agaricus bisporus extract further support the normal physiological state of mitochondria through synergistic effects. The single excipient is only physically mixed with the active ingredients, reducing interference caused by excipient interactions and ensuring that the efficacy of each active component is fully exerted.

To provide a Trichosanthes kirilowii polypeptide having a nephrotonic effect, a preparation method and use thereof.SOLUTION: In the present invention, the Trichosanthes kirilowii polypeptide with nephrotonic effect is obtained by pre-treatment of Trichosanthes kirilowii raw materials, preparation of Trichosanthes kirilowii seed liquid, preparation of crude Trichosanthes kirilowii peptide, ion-exchange chromatography, HPLC purification and other processes. The Trichosanthes kirilowii polypeptide provided in the present invention can regulate the expression of testosterone secretion-related genes and proteins in TM3 cells, improve the mitochondrial function, promote the expression of mitochondrial biosynthesis-related genes and proteins, and significantly promote the testosterone secretion of TM3 cells, and has the effect of promoting kidney tone, thereby expanding the use range of Trichosanthes kirilowii.SELECTED DRAWING: Figure 7

The present invention belongs to the field of biotechnology, and specifically relates to a Fructus Trichosanthis polypeptide having the efficacy of tonifying kidney yang, a preparation method and use thereof. The present invention prepares the Fructus Trichosanthis polypeptide having the efficacy of tonifying kidney and invigorating yang by processes such as pretreatment of a Fructus Trichosanthis raw material, preparation of a Fructus Trichosanthis seed solution, preparation of a crude Fructus Trichosanthis peptide, ion-exchange resin chromatography, and purification via high performance liquid chromatography. The Fructus Trichosanthis polypeptide provided by the present invention can modulate the expression of genes and proteins associated with secretion of testosterone in TM3 cells, enhance the function of mitochondria, accelerate the expression of genes and proteins associated with mitochondrial biogenesis, significantly promote the secretion of testosterone in TM3 cells, and has the efficacy of tonifying kidney and invigorating yang, thereby expanding the application range of Fructus Trichosanthis.

The present disclosure relates to highly purified (R)-3′-hydroxybutyl (R)-3′-hydroxybutyrate and biomedical uses thereof. In particular highly purified (R)-3′-hydroxybutyl (R)-3′-hydroxybutyrate, is provided for enhancing bodily function and treating various disease states. The methods described herein provide for production of a highly purified (R)-3′-hydroxybutyl (R)-3′-hydroxybutyrate via processes external to the human body and administering effective amounts of highly purified (R)-3′-hydroxybutyl (R)-3′-hydroxybutyrate to human subjects to achieve a range of therapeutic benefits, including but not limited to, one or more of: inhibiting inflammasome activation, reducing pro-inflammatory cytokines, improving insulin sensitivity, enhancing mitochondrial biogenesis, and promoting muscle protein synthesis. Additionally, highly purified (R)-3′-hydroxybutyl (R)-3′-hydroxybutyrate is administered in an amount and frequency conducive to one or more of: improving cognitive function, reducing oxidative stress, enhancing cardiovascular health, and supporting neuroprotection. Methods for manufacturing and purifying (R)-3′-hydroxybutyl (R)-3′-hydroxybutyrate compositions to ensure high specificity and efficacy in therapeutic applications are also provided.

Reduced muscle contractility and mitochondrial bioenergetics are the hallmarks of systolic heart failure. There is currently no therapy targeting both. The present invention shows that gene delivery of Perml via adeno-associated virus (AAV) simultaneously enhances cardiac contractility and mitochondrial biogenesis. Moreover, PERM1 interacts with Troponin C (TnC), a key contractile protein in striated muscle, and that AAV -Perml led to upregulation of TnC. Thus, gene delivery of Perml can be a novel therapeutic approach to treat or prevent systolic heart failure by simultaneously restoring cardiac contractility and mitochondrial bioenergetics.

The application discloses application of L- kynurenine in preparation of a medicine for preventing and / or treating ultraviolet light induced skin photo-damage. The application proves that L- kynurenine has a significant anti-photo-damage effect by a UVA irradiation HaCaT cell model, can enhance mitochondrial function and promote mitochondrial biogenesis, thereby improving the antioxidant capacity of cells and reducing inflammatory reactions. The application also verifies that a hydrogel containing L- kynurenine can effectively repair mouse back skin damage caused by ultraviolet light through a UVA combined with UVB irradiation back depilation mouse model, improve the water content and antioxidant capacity of the skin, and reduce inflammatory reactions, edema, roughness, erythema or eschar and other phenomena. Therefore, the application provides a reference direction for development, utilization and popularization of L- kynurenine for preparing a medicine or a medical cosmetic product for repairing skin photo-damage.

Reduced muscle contractility and mitochondrial bioenergetics are the hallmarks of systolic heart failure. There is currently no therapy targeting both. The present invention shows that gene delivery of Perml via adeno-associated virus (AAV) simultaneously enhances cardiac contractility and mitochondrial biogenesis. Moreover, PERM1 interacts with Troponin C (TnC), a key contractile protein in striated muscle, and that AAV -Perml led to upregulation of TnC. Thus, gene delivery of Perml can be a novel therapeutic approach to treat or prevent systolic heart failure by simultaneously restoring cardiac contractility and mitochondrial bioenergetics.

The invention provides application of Qixuekang in preparation of a medicine for treating renal fibrosis. Experimental research proves that the Qixuekang administration can remarkably recover the renal function of a mouse with renal fibrosis in senescence-accompanied chronic kidney diseases, reduce the mouse kidney mesenchymal fibrosis level and the levels of fibrosis markers alpha-SMA and Col1, recover the content of reductive glutathione in the mouse, improve the activity of superoxide dismutase and improve the curative effect of the kidney fibrosis in the senescence-accompanied chronic kidney diseases. Therefore, kidney fibrosis phenotypes and fibrosis-related biochemical indexes of mice are improved. Qi-blood Kang can remarkably restore kidney mesenchymal transformation related gene and protein expression, and kidney fibrosis phenotypes in chronic kidney diseases are improved by reducing related inflammatory media; qiwankang can significantly improve mitochondrial membrane potential, increase mitochondrial neogenesis related gene expression and reduce generation of active oxygen.

Orally administered low-dose formulations for medium chain di-carboxylic acids have unexpectedly a numerous of beneficial cytoprotective effects in a variety of cells. In particular, contemplated formulations compositions and methods reduce, reverse, and / or prevent liver inflammation, hepatic steatosis, and / or liver fibrosis in NASH, improve blood glucose control, and provide additional cytoprotective benefits such as stimulation of mitochondrial biogenesis, increased SIRT and NAMPT levels, increased NAD+, antioxidant capacity, and / or reduction of DNA damage.

The present disclosure provides compositions and methods for increasing mitochondrial function. The present disclosure further provides nanomaterial structures comprising high atomic vacancy concentrations which are used to stimulate mitochondrial production. The resulting mitochondria may be used for mitochondrial transplantation to treat diseases or disorders associated with decreased mitochondrial function.